UiPath (PATH) Stock Tumbles Following Analyst Downgrade Over AI Pricing Worries

Key Takeaways

• DA Davidson slashed UiPath’s rating to Underperform from Neutral, setting a $10 price target.
• Concerns stem from customer resistance to AI pricing discussed at the company’s FUSION conference and Investor Day.
• PATH shares have declined 8% in the last week, trading beneath key moving averages.
• Consensus among analysts remains at Hold with a $15.69 average target price.
• Despite exceeding Q2 revenue and earnings forecasts, company insiders offloaded more than $24 million in shares recently.

UiPath (PATH) stock faces renewed selling pressure following a rating cut from DA Davidson on Monday. The investment firm moved the automation software provider to Underperform from Neutral while slashing its price objective to $10, significantly below current trading levels.

UiPath Inc., PATH

The automation platform’s shares started trading at $12.23 and have shed 8% in the past seven days. This decline pushes the stock beneath its 50-day moving average of $14.53 and near its 200-day moving average of $12.24.

Analyst Lucky Schreiner identified pricing challenges as the primary catalyst behind the downgrade. These concerns emerged after DA Davidson representatives attended UiPath’s FUSION conference and subsequent Investor Day presentations.

During these events, UiPath outlined its vertical-focused market approach and introduced pre-built solutions designed to accelerate customer implementation. Management emphasized the company’s commitment to determinism and expanded deployments when clients integrate orchestration capabilities with automation platforms.

Customer and partner reactions at the conference proved varied. Resistance to AI pricing emerged as the most significant concern highlighted by DA Davidson in their analysis.

Analyst Community Divided on PATH Outlook

DA Davidson’s bearish stance doesn’t reflect universal sentiment. The overall Street consensus on PATH maintains a Hold rating, with a mean price objective of $15.69.

Multiple firms have reduced their targets while maintaining neutral positions. BMO Capital Markets dropped its forecast to $15 from $18, and UBS decreased its target to $15 from $19 following UiPath’s decision not to provide preliminary fiscal 2028 revenue guidance.

TD Cowen maintained a $16 price objective alongside a Hold rating, whereas RBC Capital reduced its target to $15 citing execution risks. Truist Securities moved to a $14 target, and Bank of America increased its forecast to $15 while retaining an Underperform stance.

Among all covering analysts, four assign PATH a Buy rating, fifteen recommend Hold, and two rate it Sell.

Recent Financial Performance and Insider Transactions

UiPath’s most recent quarterly results, disclosed September 3, surpassed Wall Street projections. The firm reported EPS of $0.15, in line with forecasts, on revenue of $410.26 million compared to the anticipated $397.77 million.

Top-line growth registered at 13.3% versus the prior-year period. Net profit margin reached 21.03%, with return on equity measuring 9.70%. The Street projects UiPath will deliver $0.49 in full-year EPS for the current fiscal period.

Insider dispositions have accelerated as shares declined. Raghavendra Malpani divested 40,464 shares on September 17 at $14.00 per share, totaling $566,496.

Chief Operating Officer Ashim Gupta offloaded 117,339 shares on September 11 at an average of $13.85, representing approximately $1.63 million. This transaction reduced his stake by 5.45%.

Throughout the previous 90 days, corporate insiders have disposed of 1.56 million PATH shares valued at $24.7 million collectively. Company executives and directors control 22.44% of outstanding shares.

Institutional stakeholders command a more substantial portion, holding 62.5% of available stock. Multiple investment firms expanded their holdings in recent periods, including Allworth Financial LP and Corient Private Wealth LLC.

UiPath maintains a market capitalization of $6.37 billion, trades at a PE multiple of 18.25, and exhibits a beta of 1.02. The stock’s 52-week trading range extends from $9.20 to $19.84.

The post UiPath (PATH) Stock Tumbles Following Analyst Downgrade Over AI Pricing Worries appeared first on Blockonomi.